Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY25 results:
- Total Income: Rs 509.8 crore (decreased by 0.3% QoQ, decreased by 10.6% YoY)
- EBITDA: Rs 58.2 crore (increased by 1.0% QoQ, decreased by 27.2% YoY)
- EBITDA Margin: 11.4% (increased by 10 basis points QoQ, decreased by 260 basis points YoY)
- PAT: Rs 29.7 crore (increased by 5.3% QoQ, decreased by 35.7% YoY)
- PAT Margin: 5.8% (increased by 30 basis points QoQ, decreased by 230 basis points YoY)
Commenting on the performance, Vikas Gupta, Joint Managing Director said, “Despite facing challenging geopolitical conditions, the Company has successfully maintained operational performance, demonstrating resilience in absorbing the pricing volatility of raw materials for chemicals and intermediates. With the recent approvals from various regulatory authorities, we are excited to explore untapped opportunities in regulated markets. Our commitment to enhancing operational efficiency remains steadfast as we embrace cutting-edge technology, all while striving to minimize our carbon footprint. We are dedicated to driving sustainable growth and setting new benchmarks in our industry.”
FAQ’s on IOL Chemicals & Pharmaceuticals Ltd Shares
